Zhongxing BioTech released its 2024 annual performance, with a net profit attributable to the parent company of 128 million yuan, a year-on-year decrease of 19.77%

According to the Zhitong Finance APP, Zhongxing BioTech (002772.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 1.935 billion yuan, a year-on-year increase of 0.21%. The net profit attributable to shareholders of the listed company was 128 million yuan, a year-on-year decrease of 19.77%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 91.7715 million yuan, a year-on-year decrease of 30.07%. The basic earnings per share were 0.3269 yuan. The company plans to distribute a cash dividend of 3.00 yuan (including tax) for every 10 shares to all shareholders.

In 2024, the edible mushroom industrialized planting business faces significant operational pressure and development challenges. The price of the enoki mushroom product has remained low since the second half of 2023, resulting in substantial losses this year. However, the button mushroom product, due to its higher planting threshold and relatively relaxed competition, has strong profitability. Additionally, the company has a high market share in button mushroom products, and the gross profit margin has increased, making it the main source of the company's profits